<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03704506</url>
  </required_header>
  <id_info>
    <org_study_id>Reyanning mixture</org_study_id>
    <nct_id>NCT03704506</nct_id>
  </id_info>
  <brief_title>Registration of the Study of Reyanning Mixture</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of the Efficacy and Safety of Treating Acute Tonsillitis With Reyanning Mixture Alone/in Combination With Antibiotics.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Henan University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wangjing Hospital, China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing First Hospital of integrated Chinese and Western Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of treating with acute
      tonsillitis using Reyanning mixture alone/in combination with antibiotics, and its function
      of reducing the use of antibiotics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to evaluate the efficacy,safety and the function of reducing the use of antibiotics
      of Reyanning mixture (a mixture of Chinese herbal medicine) in treating with acute
      tonsillitis, a randomized, double-blind, placebo-controlled, multicenter clinical trials will
      be established. According to the relevant regulations of the China Food and Drug
      Administration(CFDA), 144 cases need to be registered at least. The aim population is who
      suffering of acute tonsillitis from October 2018 to December 2019.These cases will be
      randomly divided into treatment group 1(Reyanning mixture +amoxil capsule
      simulator),treatment group 2(Reyanning mixture +amoxil capsule) and control group(Reyanning
      mixture simulator +amoxil capsule).Each group will be treated for 7 days and followed up for
      3 times . The main indicators include the recovery time/rate and antibiotic duration/dosage.
      And the vanish rate of single symptom/physical sign, the ratio of white blood cell count(WBC)
      recovery, the time of fever will be observed as well.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 22, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recovery time</measure>
    <time_frame>after 3 days of medication</time_frame>
    <description>The recovery time will be observed. Recovery means that the main signs and symptoms score is zero, and body temperature is below 37.3 ℃ maintaining for at least 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>recovery time</measure>
    <time_frame>after 7 days of medication</time_frame>
    <description>The recovery time will be observed. Recovery means that the main signs and symptoms score is zero, and body temperature is below 37.3 ℃ maintaining for at least 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>recovery rate</measure>
    <time_frame>after 3 days of medication</time_frame>
    <description>The recovery rate will be observed. Recovery means that the main signs and symptoms score is zero, and body temperature is below 37.3 ℃ maintaining for at least 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>recovery rate</measure>
    <time_frame>after 7 days of medication</time_frame>
    <description>The recovery rate will be observed. Recovery means that the main signs and symptoms score is zero, and body temperature is below 37.3 ℃ maintaining for at least 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>antibiotic duration</measure>
    <time_frame>after 7 days of medication</time_frame>
    <description>The duration of antibiotic will be observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>antibiotic dosage</measure>
    <time_frame>after 7 days of medication</time_frame>
    <description>The dosage of antibiotic will be observed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the vanish rate of single symptom/physical sign</measure>
    <time_frame>after 3 days of medication</time_frame>
    <description>The single symptom/physical sign include tonsil redness, pharyngeal pain, and fever.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the vanish rate of single symptom/physical sign</measure>
    <time_frame>after 7 days of medication</time_frame>
    <description>The single symptom/physical sign include tonsil redness, pharyngeal pain, and fever.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the ratio of WBC recovery</measure>
    <time_frame>after 7 days of medication</time_frame>
    <description>The ratio of WBC recovery refers to the percentage of white blood cell count which return to normal range after 7 days of medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the time of fever relieving</measure>
    <time_frame>after 7 days of medication</time_frame>
    <description>The time of fever relieving means that the duration from the first medication to the body temperature drops below 37.3℃ maintaining for at least 24 hours.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To observe if Reyanning mixture causes liver function damage.</measure>
    <time_frame>after 7 days of medication</time_frame>
    <description>to assess the liver function indicators</description>
  </other_outcome>
  <other_outcome>
    <measure>To observer if Reyanning mixture impacts renal function</measure>
    <time_frame>after 7 days of medication</time_frame>
    <description>to assess the renal function indicators ,including serum creatinine(Cr) and glomerular filtration rate( eGFR)</description>
  </other_outcome>
  <other_outcome>
    <measure>To observer if Reyanning mixture causes renal damage</measure>
    <time_frame>after 7 days of medication</time_frame>
    <description>to assess the urinalysis indicators</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Acute Tonsillitis</condition>
  <arm_group>
    <arm_group_label>treatment group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reyanning mixture+amoxil capsule simulator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reyanning mixture +amoxil capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reyanning mixture simulator +amoxil capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reyanning mixture</intervention_name>
    <description>Reyanning mixture , 20ml by mouth , 3 times per day for 7 days</description>
    <arm_group_label>treatment group 1</arm_group_label>
    <arm_group_label>treatment group 2</arm_group_label>
    <other_name>Reyanning</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amoxil capsule</intervention_name>
    <description>amoxil capsule , 0.5g by mouth , 3 times per day for 7 days</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>treatment group 2</arm_group_label>
    <other_name>amoxicillin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reyanning mixture simulator</intervention_name>
    <description>Reyanning mixture simulator , 20ml by mouth , 3 times per day for 7 days</description>
    <arm_group_label>control group</arm_group_label>
    <other_name>Reyanning simulator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amoxil capsule simulator</intervention_name>
    <description>amoxil capsule simulator , 0.5g by mouth , 3 times per day for 7 days</description>
    <arm_group_label>treatment group 1</arm_group_label>
    <other_name>amoxicillin simulator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Meet the diagnostic criteria of acute tonsillitis;

          2. Meet the traditional Chinese medicine symptom diagnostic criteria of external
             wind-heat type and excessive heat in the lung and stomach type;

          3. 18 years≤age≤65 years;

          4. course of disease within 72 hours;

          5. sign informed consent.

        Exclusion Criteria:

          1. common cold,influenza, acute laryngopharyngitis, pharyngeal diphtheria, wensang's
             isthmitis.

          2. complicated with acute tracheobronchitis,pneumonia,rheumatic fever, acute
             glomerulonephritis or rheumatic heart disease.

          3. complicated with severe angiocardiopathy, cerebrovascular disease, hemopoietic system
             disease or psychopath.

          4. liver or kidney function is abnormal(ALT&gt;1.5 times upper limit of normal; Cr&gt;upper
             limit of normal); diabetic.

          5. WBC&lt;10×109/L and neutrophilic granulocyte percentage&lt;75%;or WBC ≥20×109/L;

          6. gestational, lactating women or who planning to get pregnant within half a year.

          7. already accept similar traditional Chinese medicine or antibiotic within 48 hours
             before registered.

          8. joining other clinical trials or allergic to any drug in this trials.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanming Xie, BA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanming Xie, BA</last_name>
    <phone>86-13911112416</phone>
    <email>ktzu2018@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lianxin Wang, Doctor</last_name>
    <phone>86-13521781839</phone>
    <email>wlxing@126.com</email>
  </overall_contact_backup>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 7, 2018</study_first_submitted>
  <study_first_submitted_qc>October 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2018</study_first_posted>
  <last_update_submitted>October 10, 2018</last_update_submitted>
  <last_update_submitted_qc>October 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Yanming Xie</investigator_full_name>
    <investigator_title>Deputy director</investigator_title>
  </responsible_party>
  <keyword>Reyanning mixture</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>randomized</keyword>
  <keyword>double-blind</keyword>
  <keyword>placebo-controlled</keyword>
  <keyword>multicenter</keyword>
  <keyword>antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tonsillitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

